Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis
-
- Toshifumi Tada
- Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji
-
- Takashi Kumada
- Department of Nursing, Gifu Kyoritsu University, Ogaki
-
- Atsushi Hiraoka
- Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama
-
- Masashi Hirooka
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime
-
- Kazuya Kariyama
- Department of Gastroenterology, Okayama City Hospital, Okayama
-
- Joji Tani
- Department of Gastroenterology and Hepatology, Kagawa University, Kagawa
-
- Masanori Atsukawa
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo
-
- Koichi Takaguchi
- Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu
-
- Ei Itobayashi
- Department of Gastroenterology, Asahi General Hospital, Asahi
-
- Shinya Fukunishi
- Department of Gastroenterology, Osaka Medical College, Osaka
-
- Kunihiko Tsuji
- Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo
-
- Toru Ishikawa
- Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata
-
- Kazuto Tajiri
- Department of Gastroenterology, Toyama University Hospital, Toyama
-
- Hironori Ochi
- Hepato-biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama
-
- Satoshi Yasuda
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki
-
- Hidenori Toyoda
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki
-
- Takeshi Hatanaka
- Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi
-
- Satoru Kakizaki
- Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki
-
- Noritomo Shimada
- Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa
-
- Kazuhito Kawata
- Department of Hepatology, Hamamatsu University School of Medicine, Hamamatsu
-
- Takaaki Tanaka
- Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama
-
- Hideko Ohama
- Department of Gastroenterology, Osaka Medical College, Osaka
-
- Kazuhiro Nouso
- Department of Gastroenterology, Okayama City Hospital, Okayama
-
- Asahiro Morishita
- Department of Gastroenterology and Hepatology, Kagawa University, Kagawa
-
- Akemi Tsutsui
- Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu
-
- Takuya Nagano
- Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu
-
- Norio Itokawa
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo
-
- Tomomi Okubo
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo
-
- Taeang Arai
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo
-
- Michitaka Imai
- Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata
-
- Atsushi Naganuma
- Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki
-
- Tomoko Aoki
- Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan
-
- Yohei Koizumi
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime
-
- Shinichiro Nakamura
- Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji
-
- Kouji Joko
- Hepato-biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama
-
- Yoichi Hiasa
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime
-
- Masatoshi Kudo
- Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan
Abstract
<jats:sec> <jats:title>Objective</jats:title> <jats:p>The use of Glasgow prognostic score (GPS), calculated using the serum C-reactive protein and albumin levels, to predict the outcomes of patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib was investigated in this study.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>A total of 508 patients with Child-Pugh class A HCC treated with lenvatinib were included in this study.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>The median overall and progression-free survivals were 20.4 months [95% confidence interval (CI), 17.7–23.2 months] and 7.5 months (95% CI, 6.8–8.5 months), respectively. The median overall survivals of patients with a GPS of 0, 1, and 2 were 28.5, 16.0, and 9.1 months, respectively (<jats:italic toggle="yes">P</jats:italic> < 0.001). When adjusted for age, sex, performance status, etiology, α-fetoprotein, macroscopic vascular invasion, extrahepatic spread, history of sorafenib therapy, and GPS, a GPS of 1 [hazard ratio (HR), 1.664; 95% CI, 1.258–2.201; <jats:italic toggle="yes">P</jats:italic> < 0.001] and a GPS of 2 (HR, 2.664; 95% CI, 1.861–3.813; <jats:italic toggle="yes">P</jats:italic> < 0.001) were found to be independently associated with overall survival. The median progression-free survivals of patients with a GPS of 0, 1, and 2 were 8.8, 6.8, and 3.8 months, respectively (<jats:italic toggle="yes">P</jats:italic> < 0.001). When adjusted for the same factors of overall survival, a GPS of 2 (HR, 2.010; 95% CI, 1.452–2.784; <jats:italic toggle="yes">P</jats:italic> < 0.001) was found to be independently associated with progression-free survival. As the albumin–bilirubin with tumor node metastasis score increased, the proportion of patients with a GPS of 1 or 2 increased (<jats:italic toggle="yes">P</jats:italic> < 0.001).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>GPS can be used to predict survival in patients with unresectable HCC who were treated with lenvatinib.</jats:p> </jats:sec>
Journal
-
- European Journal of Gastroenterology & Hepatology
-
European Journal of Gastroenterology & Hepatology 34 (8), 857-864, 2022-06-29
Ovid Technologies (Wolters Kluwer Health)
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1360580232415629440
-
- ISSN
- 0954691X
-
- Data Source
-
- Crossref
- KAKEN